Cargando…
HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL
INTRODUCTION: The aim of this study was to evaluate the effect of using an intra-articular injection of hylan G-F 20 (HA group) on primary shoulder osteoarthritis compared with an intra-articular triamcinolone injection (T group). MATERIALS AND METHODS: The patients were randomized into 2 groups: in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
ATHA EDITORA
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979357/ https://www.ncbi.nlm.nih.gov/pubmed/35431635 http://dx.doi.org/10.1590/1413-785220223001e244410 |
_version_ | 1784681158827573248 |
---|---|
author | TORTATO, SIMONE POCHINI, ALBERTO DE CASTRO ANDREOLI, CARLOS VICENTE COHEN, CARINA LARA, PAULO HENRIQUE SCHMIDT BELANGERO, PAULO SANTORO EJNISMAN, BENNO |
author_facet | TORTATO, SIMONE POCHINI, ALBERTO DE CASTRO ANDREOLI, CARLOS VICENTE COHEN, CARINA LARA, PAULO HENRIQUE SCHMIDT BELANGERO, PAULO SANTORO EJNISMAN, BENNO |
author_sort | TORTATO, SIMONE |
collection | PubMed |
description | INTRODUCTION: The aim of this study was to evaluate the effect of using an intra-articular injection of hylan G-F 20 (HA group) on primary shoulder osteoarthritis compared with an intra-articular triamcinolone injection (T group). MATERIALS AND METHODS: The patients were randomized into 2 groups: in the HA group a single dose of intra-articular hylan G-F 20 was administered and in the T control group a dose of triamcinolone 20 mg was administered. The participants were evaluated at 1 week, 1, 3, and 6 months after the procedure. The patients were evaluated for pain, range of motion, Constant score, modified UCLA score, and SPADI. RESULTS: Seventy patients met the inclusion criteria and were randomized to the HA (38) and T (32) groups. Improvements in range of motion were significant (p > 0.05). We observed decreases in the general visual analog scale (VAS) for pain in both groups, especially in the cases of mild and moderate arthritis that received hyaluronic acid (mean values from 8.1 initially to 4.9 after 6 months) (p = 0). CONCLUSIONS: Both injections led to a decrease in pain and an increase in patient satisfaction. The results tend to be better and longer lasting in patients receiving hyaluronic acid. Level of evidence II b; Cohort study. |
format | Online Article Text |
id | pubmed-8979357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | ATHA EDITORA |
record_format | MEDLINE/PubMed |
spelling | pubmed-89793572022-04-15 HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL TORTATO, SIMONE POCHINI, ALBERTO DE CASTRO ANDREOLI, CARLOS VICENTE COHEN, CARINA LARA, PAULO HENRIQUE SCHMIDT BELANGERO, PAULO SANTORO EJNISMAN, BENNO Acta Ortop Bras Original Article INTRODUCTION: The aim of this study was to evaluate the effect of using an intra-articular injection of hylan G-F 20 (HA group) on primary shoulder osteoarthritis compared with an intra-articular triamcinolone injection (T group). MATERIALS AND METHODS: The patients were randomized into 2 groups: in the HA group a single dose of intra-articular hylan G-F 20 was administered and in the T control group a dose of triamcinolone 20 mg was administered. The participants were evaluated at 1 week, 1, 3, and 6 months after the procedure. The patients were evaluated for pain, range of motion, Constant score, modified UCLA score, and SPADI. RESULTS: Seventy patients met the inclusion criteria and were randomized to the HA (38) and T (32) groups. Improvements in range of motion were significant (p > 0.05). We observed decreases in the general visual analog scale (VAS) for pain in both groups, especially in the cases of mild and moderate arthritis that received hyaluronic acid (mean values from 8.1 initially to 4.9 after 6 months) (p = 0). CONCLUSIONS: Both injections led to a decrease in pain and an increase in patient satisfaction. The results tend to be better and longer lasting in patients receiving hyaluronic acid. Level of evidence II b; Cohort study. ATHA EDITORA 2022-01-28 /pmc/articles/PMC8979357/ /pubmed/35431635 http://dx.doi.org/10.1590/1413-785220223001e244410 Text en https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article TORTATO, SIMONE POCHINI, ALBERTO DE CASTRO ANDREOLI, CARLOS VICENTE COHEN, CARINA LARA, PAULO HENRIQUE SCHMIDT BELANGERO, PAULO SANTORO EJNISMAN, BENNO HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL |
title | HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL |
title_full | HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL |
title_fullStr | HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL |
title_full_unstemmed | HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL |
title_short | HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL |
title_sort | hylan g-f 20 versus triamcinolone in the treatment of primary shoulder osteoarthritis. randomized trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979357/ https://www.ncbi.nlm.nih.gov/pubmed/35431635 http://dx.doi.org/10.1590/1413-785220223001e244410 |
work_keys_str_mv | AT tortatosimone hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial AT pochinialbertodecastro hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial AT andreolicarlosvicente hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial AT cohencarina hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial AT larapaulohenriqueschmidt hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial AT belangeropaulosantoro hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial AT ejnismanbenno hylangf20versustriamcinoloneinthetreatmentofprimaryshoulderosteoarthritisrandomizedtrial |